



# SPAFID CONNECT

Informazione Regolamentata n. 0957-56-2020	Data/Ora Ricezione 09 Luglio 2020 07:26:49	MTA
--	--	-----

Societa' : DiaSorin

Identificativo : 134793

Informazione  
Regolamentata

Nome utilizzatore : DIASORINN02 - Fava

Tipologia : REGEM

Data/Ora Ricezione : 09 Luglio 2020 07:26:49

Data/Ora Inizio : 09 Luglio 2020 07:26:50

Diffusione presunta

Oggetto : DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study

*Testo del comunicato*

Vedi allegato.

## **DIASORIN WILL PROVIDE THE UK GOVERNMENT WITH ITS LIAISON® SARS-CoV-2 S1/S2 IGG SEROLOGY KIT FOR COVID-19 TESTING TO RUN A NATIONAL SCREENING STUDY**

**Saluggia - July 9, 2020** - DiaSorin (FTSE MIB: DIA) announces that its LIAISON® SARS-CoV-2 S1/S2 IgG test was chosen by NHS England, the UK National Health Service, to assist with the completion of a National screening, tracking the impact and the circulation of the virus on the UK population.

The test was CE marked on April 17, 2020; it then received, third in the US, the Emergency Use Authorization (EUA) by the American Food and Drug Administration on April 25, 2020, first in Canada, the authorization from Health Canada on May 18, 2020, and the authorization by ANVISA, the Brazilian Health Regulatory Agency, on May 25, 2020.

Thanks to its extreme quality, the UK is the fourth country where the test has been chosen to run a national epidemiological study.

Fernando Davico, Corporate Vice President Sales EMEA, APAC & LATAM at DiaSorin, commented, *“Our test will assist with the diagnosis of COVID-19 and assess the immunological status of infected patients, providing a concrete diagnostic tool to study the immune response to the virus and understand the circulation of the virus also amongst the UK population”*.

The test is based on the chemiluminescence technology for the quantitative and qualitative determination of IgG antibodies against SARS-CoV-2 S1 and S2 proteins in serum or human plasma samples and identifies the presence of antibodies in patients who have been infected with SARS-CoV-2.

The LIAISON® SARS-CoV-2 S1/S2 IgG test is currently available on over 5,000 LIAISON® XL platforms installed worldwide, with performance of 170 patient samples per hour and with the first result being released in just 35 minutes, increasing testing capacity and allowing productivity improvement to mitigate the impact of this virus.

*“The choice of the UK government today follows a series of similar decisions from other governments”*, commented Carlo Rosa, Chief Executive Officer of the DiaSorin Group. *“I’m proud that NHS will initiate such a relevant screening for the UK population with our serology test, appreciating, once again, our capability in providing quality products on the market.”*

### **For additional information, please contact:**

**Riccardo Fava**  
Corporate Vice President Communication & Investor Relations  
Tel: +39.0161.487988  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Emanuela Salvini**  
Investor Relator  
Tel: +39.0161.487567  
[emanuela.salvini@diasorin.it](mailto:emanuela.salvini@diasorin.it)

### **DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasoringroup.com](http://www.diasoringroup.com)

Fine Comunicato n.0957-56

Numero di Pagine: 3